Nabriva Therapeutics (nbrv)
Similarly to GMDA, Nabriva Therapeutics is a company that also has 2 premiere projects in the works and has a lot of promising developments going on. Nabriva's lead drug XENLETA, which treats patients with community-acquired bacterial pneumonia (CABP), recently won FDA approval and is being distributed in the U.S. since August. Nabriva also recently acquired Zvante Therapeutics and added CONTEPO to its portfolio; an injection for the treatment of complicated urinary tract infections. In contrast to XENLETA, however, CONTEPO has yet to gain FDA approval.
Northland analyst Carl Brynes is forecasting "peak global sales of XENLETA at $1B, supported by XENLETA's clinical differentiation and oral/IV dosing forms." With a market cap of only $130.58 million, the analyst sees huge upside for NBRV stock, as he reiterates an Outperform rating and $12.50 price target. (To watch Brynes' track record, click here)
Wedbush analyst Robert Driscoll added, "We see XENLETA’s profile as well suited for the treatment of CABP, given its favorable safety and efficacy profile, a narrow but CABP-targeted spectrum, and flexible IV to oral/oral dosing. Importantly, two Ph 3 studies have demonstrated efficacy with a short treatment course of 5-7 days, which we note aligns with antibiotic stewardship principles. With recent favorable changes to the reimbursement landscape and a clear plan in place for lefamulin commercialization, plus clarification around second asset CONTEPO NDA resubmission timelines, we believe NBRV shares are currently undervalued."
All in all, the drug maker is without question a Wall Street favorite, considering TipRanks analytics indicate NBRV as a Strong Buy. Out of 5 analysts polled in the last 3 months, all 5 are bullish on the stock. With a return potential of nearly 390%, the stock's consensus target price stands at $8.70.
